mRNA-1273, CVnCoV, LUNAR-CoV19, and LNP-nCoVsaRNA mRNA vaccines used the template encoding the full-length S protein with 2P substitutions at K986 and V987 positions to produce the stable pre-fusion form of S protein [73]. Pfizer/BioNTech have developed two immunogens, the RBD (BNT162b1...
mRNA-1273 (Moderna) mRNA-based vaccine Sequence optimised mRNA that encodes for S-protein formulated within lipid nanoparticle. Phase III 33065034 NCT04470427 NVX-CoV2373 (Novavax) Recombinant protein-based vaccine S-protein purified from Baculovirus with saponin-based Matrix MTM adjuvant. Phase III ...
mRNA vaccines are acquired from mRNA, encapsulated by lipid nanoparticles (LNP) or other delivery systems (Forchette et al.2021). The mRNA vaccine contains genetic code to make SARS-CoV-2 S protein; when it is injected into the body, COVID-19 virus spike protein is created and recognized ...
In March 2020, it took only 42 days for Moderna’s mRNA-1273 to enter phase I clinical trials as the very first mRNA vaccine against COVID-19 in the United States (NCT04283461). Several other SARS-CoV-2 mRNA vaccine candidates are currently in development worldwide, which further proves ...
LNP can protect mRNA against the degradation of nuclease71and further enhance the efficacy of mRNA vaccines. The capsulation of mRNA with LNP can effectively transfer mRNA into cells and induce a strong immune response; thus is widely used in most mRNA vaccines, including BNT162b2 and mRNA-...
Moderna is an American-based company in Cambridge, Massachusetts, that developed an mRNA-based vaccine, mRNA-1273, collaborating with the National Institute of Allergy and Infectious Diseases (NIAID). mRNA-1273 is a lipid-nanoparticle (LNP) encapsulated mRNA that expresses the prefusion stabilized spi...
Moderna Therapeutics ChikungunyamRNA-1944 LNP-mRNAAntigen:IgG Ab with activity against CHIK IV0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1 mg/kg 22 (18–50) Phase I(NCT03829384)Dose escalation. Ongoing – Moderna Therapeutics Chikungunya VAL-181388 (mRNA-1388) mRNAAntigens: chikungunya structural C ...
RNA LNP encapsulated mRNA “mRNA-1273.351.A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant." Moderna/NIAID Phase 4 RNA BNT162b2 (3 LNP-mRNAs), also known as “Comirnaty" BioNTech/Fo...
There is a difference in the amount of LNPs contained in the two vaccines: in the dose of Comirnaty (BNT162b2—Pfizer/Biontech), to be administered to subjects aged >12 years, there are 30 micrograms/dose [76]; while in the Moderna vaccine (mRNA-1273) there are 100 micrograms/dose [...
The other nucleoside-modified mRNA-LNP vaccine, mRNA-1273 (elasomeran, Spikevax), encoding the SARS-CoV-2 spike protein was manufactured by Moderna in early 2020. Overall, the two types of mRNA vaccines were found to be extremely efficient in avoiding COVID-19-related hospital admissions due...